Media

Newsroom

Back to news

FDA Approves Galderma’s prescription-strength Differin Gel for over-the-counter use in treatment of acne in the U.S.

July 15, 2016

Lausanne, July 15, 2016 – Galderma, Nestlé Skin Health’s medical solutions business, announced that the U.S. Food and Drug Administration (FDA) has approved Differin Gel (adapalene gel 0.1%) as an over-the-counter (OTC) treatment for acne. Discovered and developed in the company’s research center, Differin was first approved as a prescription drug in the U.S. in 1996.  This new approval as an OTC drug allows acne sufferers to access this highly effective acne treatment without first requiring a doctor’s prescription. 

Differin Gel is the first and only OTC acne product containing a prescription-strength retinoid, and is the first new active ingredient approved by the FDA in the OTC acne category in over three decades. 

Acne is the most common skin condition in the United States, affecting up to 60 million teens and adults annually.(1)

Read the full Galderma press release

(1) Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E and others. The burden of skin diseases: 2004: A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology, Vol. 55, Issue 3, p490-500 Published in issue September 2006. 

Back to top